AstraZeneca is scheduled to report results for the third quarter on Tuesday. Here is what to know. CORE EARNINGS PER SHARE: One of the Anglo-Swedish pharmaceutical major's preferred metrics, core EPS ...
ENRICHED CTCS AND CTDNA PROVIDES COMPLEMENTARY INFORMATION IN NSCLC PATIENTS TREATED WITH ASTRAZENECA'S OSIMERTINIBThe addition of CTC-DNA analysis to clinical trials could identify patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback